Carys Hogan1, Joanna Le Noury1, David Healy1, Derelie Mangin2. 1. North Wales Department of Psychological Medicine, Bangor, Wales, UK. 2. David Braley & Nancy Gordon Chair of Family Medicine, Department of Family Medicine, McMaster University, ON, Canada.
Abstract
BACKGROUND: There have been reports for over a decade linking serotonin reuptake inhibitors, finasteride and isotretinoin with enduring sexual dysfunction after treatment stops. OBJECTIVE: To explore the clinical pictures linked to all 3 drugs. METHODS: We have selected 120 reports to RxISK.org reporting the problem and mined these for data on age, gender, drug of use, and impact of the problem. RESULTS: The data make it clear that the three drugs show extensive overlap in symptom profile, regardless of sex or country of origin. CONCLUSIONS: The availability of 120 reports from over 20 countries add to the case for the validity of the syndrome. This is severe and enduring condition can result in death. An understanding of its physiology and an approach to treatment are needed.
BACKGROUND: There have been reports for over a decade linking serotonin reuptake inhibitors, finasteride and isotretinoin with enduring sexual dysfunction after treatment stops. OBJECTIVE: To explore the clinical pictures linked to all 3 drugs. METHODS: We have selected 120 reports to RxISK.org reporting the problem and mined these for data on age, gender, drug of use, and impact of the problem. RESULTS: The data make it clear that the three drugs show extensive overlap in symptom profile, regardless of sex or country of origin. CONCLUSIONS: The availability of 120 reports from over 20 countries add to the case for the validity of the syndrome. This is severe and enduring condition can result in death. An understanding of its physiology and an approach to treatment are needed.
Entities:
Keywords:
SSRIs; erectile dysfunction; finasteride; genital anesthesia; isotretinoin; loss of libido
Authors: David Healy; Audrey Bahrick; Maarten Bak; Angelo Barbato; Rocco Salvatore Calabrò; Barbara M Chubak; Fiammetta Cosci; Antonei B Csoka; Barbara D'Avanzo; Silvia Diviccaro; Silvia Giatti; Irwin Goldstein; Heiko Graf; Wayne J G Hellstrom; Michael S Irwig; Emmanuele A Jannini; Paddy K C Janssen; Mohit Khera; Manoj Therayil Kumar; Joanna Le Noury; Michał Lew-Starowicz; David E J Linden; Celine Lüning; Dee Mangin; Roberto Cosimo Melcangi; Omar Walid Muquebil Ali Al Shaban Rodríguez; Jalesh N Panicker; Arianna Patacchini; Amy M Pearlman; Caroline F Pukall; Sanjana Raj; Yacov Reisman; Rachel S Rubin; Rudy Schreiber; Stuart Shipko; Barbora Vašečková; Ahad Waraich Journal: Int J Risk Saf Med Date: 2022
Authors: F Borgo; A D Macandog; S Diviccaro; E Falvo; S Giatti; G Cavaletti; R C Melcangi Journal: J Endocrinol Invest Date: 2020-09-19 Impact factor: 4.256
Authors: Riya R Kanherkar; Bruk Getachew; Joseph Ben-Sheetrit; Sudhir Varma; Thomas Heinbockel; Yousef Tizabi; Antonei B Csoka Journal: Int J Genomics Date: 2018-07-25 Impact factor: 2.326